A phase I dose-escalation sequential-cohort of the safety tolerability and pharmacokinetics of intravenous AVE005 [aflibercept] (VEGF Trap) administered every 2 weeks in combination with weekly intravenous gemcitabine then with biweekly intravenous gemcitabine plus oxaliplatin in subjects with advanced solid malignancies

Trial Profile

A phase I dose-escalation sequential-cohort of the safety tolerability and pharmacokinetics of intravenous AVE005 [aflibercept] (VEGF Trap) administered every 2 weeks in combination with weekly intravenous gemcitabine then with biweekly intravenous gemcitabine plus oxaliplatin in subjects with advanced solid malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2008

At a glance

  • Drugs Aflibercept (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jun 2008 Interim results were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.
    • 07 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top